Log in automatically

Log in | New user?


Protox doses first patient in Phase 2 BPH clinical trial
                   
newswire.ca     May 15, 2008            

VANCOUVER, May 15 /CNW/ - Protox Therapeutics Inc. (TSX:PRX), a leader in the development of receptor targeted fusion proteins, today announced the enrolment and successful dosing of the first patient in a Phase 2 clinical trial evaluating PRX302 to treat benign prostatic hyperplasia (BPH), or...


Full Coverage:

Protox Reports 2008 First Quarter Results

newswire.ca     May 13, 2008          

VANCOUVER, May 13 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today released first quarter 2008 financial results for the 3 months ended March 31, 2008 (2008 Q1). "Protox made substantial progress during the first quarter...

analysis/comments